FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896868187> ?p ?o ?g. }

• W2896868187 endingPage "666" @default.
• W2896868187 startingPage "658" @default.
• W2896868187 abstract "Central nervous system (CNS) infections caused by free-living amoebae such as Acanthamoeba species and Naegleria fowleri are rare but fatal. A major challenge in the treatment against the infections caused by these amoebae is the discovery of novel compounds that can effectively cross the blood-brain barrier to penetrate the CNS. It is logical to test clinically approved drugs against CNS diseases for their potential antiamoebic effects since they are known for effective blood-brain barrier penetration and affect eukaryotic cell targets. The antiamoebic effects of clinically available drugs for seizures targeting gamma-amino butyric acid (GABA) receptor and ion channels were tested against Acanthamoeba castellanii belonging to the T4 genotype and N. fowleri. Three such drugs, namely, diazepam (Valium), phenobarbitone (Luminal), phenytoin (Dilantin), and their silver nanoparticles (AgNPs) were evaluated against both trophozoites and cysts stage. Drugs alone and drug conjugated silver nanoparticles were tested for amoebicidal, cysticidal, and host-cell cytotoxicity assays. Nanoparticles were synthesized by sodium borohydride reduction of silver nitrate with drugs as capping agents. Drug conjugated nanoconjugates were characterized by ultraviolet–visible (UV–vis) and Fourier transform infrared (FT-IR) spectroscopies and atomic force microscopy (AFM). In vitro moebicidal assay showed potent amoebicidal effects for diazepam, phenobarbitone, and phenytoin-conjugated AgNPs as compared to drugs alone against A. castellanii and N. fowleri. Furthermore, both drugs and drug conjugated AgNPs showed compelling cysticidal effects. Drugs conjugations with silver nanoparticles enhanced their antiacanthamoebic activity. Interestingly, amoeba-mediated host-cell cytotoxicity was also significantly reduced by drugs alone as well as their nanoconjugates. Since, these drugs are being used to target CNS diseases, their evaluation against brain-eating amoebae seems feasible due to advantages such as permeability of the blood-brain barrier, established pharmacokinetics and dynamics, and United States Food and Drug Administration (FDA) approval. Given the limited availability of effective drugs against brain-eating amoebae, the clinically available drugs tested here present potential for further in vivo studies." @default.
• W2896868187 created "2018-10-26" @default.
• W2896868187 creator A5000801166 @default.
• W2896868187 creator A5019225101 @default.
• W2896868187 creator A5033070497 @default.
• W2896868187 creator A5043856578 @default.
• W2896868187 creator A5091775788 @default.
• W2896868187 date "2018-10-15" @default.
• W2896868187 modified "2023-10-16" @default.
• W2896868187 title "Clinically Approved Drugs against CNS Diseases as Potential Therapeutic Agents To Target Brain-Eating Amoebae" @default.
• W2896868187 cites W1972449396 @default.
• W2896868187 cites W1990229031 @default.
• W2896868187 cites W2003341565 @default.
• W2896868187 cites W2005113942 @default.
• W2896868187 cites W2011168522 @default.
• W2896868187 cites W2020037351 @default.
• W2896868187 cites W2039860301 @default.
• W2896868187 cites W2045274557 @default.
• W2896868187 cites W2046599611 @default.
• W2896868187 cites W2066685510 @default.
• W2896868187 cites W2080072810 @default.
• W2896868187 cites W2081376387 @default.
• W2896868187 cites W2089034042 @default.
• W2896868187 cites W2096296061 @default.
• W2896868187 cites W2098530184 @default.
• W2896868187 cites W2103081433 @default.
• W2896868187 cites W2113130884 @default.
• W2896868187 cites W2132503932 @default.
• W2896868187 cites W2141237239 @default.
• W2896868187 cites W2145691870 @default.
• W2896868187 cites W2162785848 @default.
• W2896868187 cites W2163151727 @default.
• W2896868187 cites W2166790009 @default.
• W2896868187 cites W2171575428 @default.
• W2896868187 cites W2278094234 @default.
• W2896868187 cites W2381110532 @default.
• W2896868187 cites W2417516546 @default.
• W2896868187 cites W2507326974 @default.
• W2896868187 cites W2513060074 @default.
• W2896868187 cites W2516255968 @default.
• W2896868187 cites W2518675083 @default.
• W2896868187 cites W2758818284 @default.
• W2896868187 cites W2772943690 @default.
• W2896868187 cites W2774524325 @default.
• W2896868187 cites W2783672398 @default.
• W2896868187 doi "https://doi.org/10.1021/acschemneuro.8b00484" @default.
• W2896868187 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30346711" @default.
• W2896868187 hasPublicationYear "2018" @default.
• W2896868187 type Work @default.
• W2896868187 sameAs 2896868187 @default.
• W2896868187 citedByCount "28" @default.
• W2896868187 countsByYear W28968681872019 @default.
• W2896868187 countsByYear W28968681872020 @default.
• W2896868187 countsByYear W28968681872021 @default.
• W2896868187 countsByYear W28968681872022 @default.
• W2896868187 countsByYear W28968681872023 @default.
• W2896868187 crossrefType "journal-article" @default.
• W2896868187 hasAuthorship W2896868187A5000801166 @default.
• W2896868187 hasAuthorship W2896868187A5019225101 @default.
• W2896868187 hasAuthorship W2896868187A5033070497 @default.
• W2896868187 hasAuthorship W2896868187A5043856578 @default.
• W2896868187 hasAuthorship W2896868187A5091775788 @default.
• W2896868187 hasConcept C109316439 @default.
• W2896868187 hasConcept C118552586 @default.
• W2896868187 hasConcept C155672457 @default.
• W2896868187 hasConcept C171250308 @default.
• W2896868187 hasConcept C185592680 @default.
• W2896868187 hasConcept C192562407 @default.
• W2896868187 hasConcept C202751555 @default.
• W2896868187 hasConcept C203014093 @default.
• W2896868187 hasConcept C2778186239 @default.
• W2896868187 hasConcept C2778337148 @default.
• W2896868187 hasConcept C2778621254 @default.
• W2896868187 hasConcept C2780035454 @default.
• W2896868187 hasConcept C2781155112 @default.
• W2896868187 hasConcept C31499863 @default.
• W2896868187 hasConcept C55493867 @default.
• W2896868187 hasConcept C71924100 @default.
• W2896868187 hasConcept C98274493 @default.
• W2896868187 hasConceptScore W2896868187C109316439 @default.
• W2896868187 hasConceptScore W2896868187C118552586 @default.
• W2896868187 hasConceptScore W2896868187C155672457 @default.
• W2896868187 hasConceptScore W2896868187C171250308 @default.
• W2896868187 hasConceptScore W2896868187C185592680 @default.
• W2896868187 hasConceptScore W2896868187C192562407 @default.
• W2896868187 hasConceptScore W2896868187C202751555 @default.
• W2896868187 hasConceptScore W2896868187C203014093 @default.
• W2896868187 hasConceptScore W2896868187C2778186239 @default.
• W2896868187 hasConceptScore W2896868187C2778337148 @default.
• W2896868187 hasConceptScore W2896868187C2778621254 @default.
• W2896868187 hasConceptScore W2896868187C2780035454 @default.
• W2896868187 hasConceptScore W2896868187C2781155112 @default.
• W2896868187 hasConceptScore W2896868187C31499863 @default.
• W2896868187 hasConceptScore W2896868187C55493867 @default.
• W2896868187 hasConceptScore W2896868187C71924100 @default.
• W2896868187 hasConceptScore W2896868187C98274493 @default.
• W2896868187 hasFunder F4320335555 @default.
• W2896868187 hasIssue "1" @default.

• next